Research Article
Adaptive Immunity in Ankylosing Spondylitis: Phenotype and Functional Alterations of T-Cells before and during Infliximab Therapy
Table 1
Prevalence and ratios of T-cell subsets in ankylosing spondylitis patients before and during infliximab (IFX) therapy.
| | Members of adaptive immunity | Healthy controls | Before IFX therapy | Week 2 after IFX therapy | Week 6 after IFX therapy |
| | CD4+ | 35.80 [29.43-40.95] | 42.7 [38.35–48.65]* | 47.10 [43.00–49.10]* | 44.30 [42.15–48.85]* | | CD4+CD45RA+ | 49.50 [40.68–61.68] | 50.80 [45.20–65.95] | 50.90 [36.20–55.40]# | 42.55 [39.55–60.78]# | | CD4+CD25+ | 7.55 [6.20–7.88] | 4.82 [4.22–5.42]* | 3.92 [3.60–4.85]* | 4.35 [4.04–4.98]* | | CD4+CD69+ | 3.23 [2.83–4.48] | 3.05 [2.72–3.28] | 3.04 [2.69–3.43] | 2.88 [2.21–3.36] | | CD4+HLA-DR+ | 2.8 [2.53–3.81] | 3.03 [2.09–3.46] | 1.95 [1.56–2.33] | 2.89 [2.21–3.51] | | CD4+CD45RO+ | 42.95 [33.33–49.65] | 41.50 [29.40–49.55] | 45.50 [37.80–54.60] | 47.45 [33.10–54.78]# |
| | Th1 | 9.81 [8.95–12.53] | 12.90 [11.75–13.80]* | 14.00 [11.50–15.70]* | 13.80 [12.43–18.83]* | | Th2 | 4.54 [4.19–4.84] | 9.18 [7.32–11.45]* | 8.70 [7.98–11.30]* | 10.90 [8.32–12.50]* | | Th1/Th2 ratio | 2.38 [1.95–2.64] | 1.31 [1.06–1.85]* | 1.40 [1.16–1.83]* | 1.38 [1.11–1.72]* | | Th17 | 0.69 [0.60–0.77] | 1.18 [1.02–1.69]* | 1.2 [0.84–1.55]* | 1.26 [0.91–1.51]* | | Treg | 4.42 [3.76–5.58] | 4.45 [3.57–5.51] | 4.29 [3.66–5.72] | 4.42 [4.05–5.24] | | Th17/Treg ratio | 0.14 [0.13–0.21] | 0.27 [0.19–0.45]* | 0.25 [0.17–0.39]* | 0.29 [0.18–0.37]* |
| | CD8+ | 18.00 [14.35–27.98] | 17.70 [14.65–21.45] | 18.30 [14.20–21.90] | 16.65 [14.43–21.60] | | CD8+CD45RA+ | 62.85 [53.38–75.78] | 70.30 [61.70–78.75] | 69.10 [55.20–72.50] | 60.20 [54.43–70.33] | | CD8+CD25+ | 2.84 [1.87–4.06] | 2.81 [2.23–3.63] | 2.85 [2.07–3.23] | 3.29 [1.84–3.54] | | CD8+CD69+ | 4.0 [3.53–12.78] | 4.88 [3.37–5.89] | 3.71 [3.26–6.77] | 5.06 [3.55–6.27] | | CD8+HLA-DR+ | 3.58 [3.10–5.31] | 3.43 [2.95–4.33] | 4.37 [2.93–5.15] | 3.57 [2.91–5.15] | | CD8+CD45RO+ | 23.65 [15.90–28.15] | 19.40 [14.25–28.20] | 26.30 [19.10–34.90] | 28.45 [18.53–40.20] | | CD4/CD8 ratio | 2.07 [1.32–2.83] | 2.26 [2.02–3.15] | 2.61 [1.99–3.21] | 2.82 [1.90–3.36] |
|
|
Data are expressed as median [interquartile range] *versus control ; #versus before IFX .
|
